Sun Pharmaceutical Industries
Andheri Kurla Road
207 articles with Sun Pharmaceutical Industries
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis
Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) Due to N-Nitrosodimethylamine (NDMA) Content Above the Acceptable Daily Intake (ADI) Limit
Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. is voluntarily recalling one lot of RIOMET ER™, 500 mg per 5 mL to the consumer level.
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the District of New Jersey with docket number 3:20-cv-12588, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Indu
Orexo AB, announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited.
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries presented data analyses for two of its specialty medicines – ODOMZO® (sonidegib) and LEVULAN® KERASTICK®
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA™ (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries presented further evidence of the long-term use and cost-effectiveness of ILUMYATM
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience
The breadth of continued research in plaque psoriasis, psoriatic arthritis, basal cell carcinoma, and actinic keratoses underscores Sun Pharma's commitment to dermatology HCPs and patients [11-June-2020] PRINCETON, N.J. , June 11, 2020 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) "Sun Pharma" today announced 25 data abstracts from its dermatology p
Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment
Sun Pharmaceutical Industries, Inc., USA, (SPII),a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (‘together Sun Pharma,’ Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715), announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States.
RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) is the first and only U.S. FDA-approved extended-release liquid formulation of metformin
Feb. 10, 2020 12:45 UTC “Take on Acne” ad campaign emphasizes the discomfort and disruption caused by acne, especially among teens and young adults PRINCETON, N.J.--( BUSINESS WIRE )-- Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together “Sun Pharma”), today announced the launch of Take on Acne – a new advertising campaign designed to raise awareness of the profound imp
Cipher Pharmaceuticals Inc. is pleased to announce that Sun Pharmaceutical Industries Ltd., the Company's U.S. marketing partner for Absorica®, has launched ABSORICA LD™ capsules in the U.S for the management of severe recalcitrant nodular acne in patients 12 years of age and older.
Sun Pharma Introduces ABSORICA LD™ (Isotretinoin) Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.
Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has launched ABSORICA LD™ capsules in U.S. for the management of severe recalcitrant nodular acne in patients 12 years of age and older.
Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India- Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually –
Rockwell Medical, Inc. announced that it has entered into license and supply agreements with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd., for the rights to commercialize Triferic in India.
Sun Pharmaceutical Industries Ltd. announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle™ in the U.S. for oral use.
CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™ technology
XELPROS™ 0.005%, the only FDA-approved Benzalkonium chloride-free formulation of latanaprost, was recently launched by Sun Pharma for the treatment of Glaucoma or Ocular Hypertension
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing
Sun Pharmaceutical Industries Ltd. announced the U.S. launch of Ezallor Sprinkle™ capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks MUMB
Use of ready-to-infuse bags eliminates steps in the complex chemotherapy preparation process, reducing exposure and mitigating inherent provider and patient safety risks
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA™ for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy of Dermatology (AAD) from March 1 – 5 in Washington, DC.